Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: A 24-week, double-blind, randomized trial

Diabetic Medicine

Volumn 25, Issue 4, 2008, Pages 435-441

  Pan, C ^b   Yang, W ^c   Barona, J P ^d   Wang, Y ^a,b   Niggli, M ^a   Mohideen, P ^a   Foley, J E ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^d Hospital de Merida   (Spain)

Author keywords

DPP 4; GLP 1; HbA1c; Incretin hormones

Indexed keywords

ACARBOSE; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; VILDAGLIPTIN;

ABDOMINAL DISTENSION; ADULT; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEART PALPITATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION;

ACARBOSE; ADAMANTANE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NITRILES; PYRROLIDINES; TREATMENT OUTCOME;

EID: 41749106662     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2008.02391.x     Document Type: Article

References (20)

1. Ahren B, Landin-Olsson M, Jansson P-A, Svenson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004 89 : 2078 2084.
2. Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y et al. The dipeptidyl peptidase iv inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007 92 : 1249 1255.
3. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005 90 : 4888 4894.
4. Matikainen N, Mänttäri S, Schweizer A, Ulvestad A, Mills D, Dunning BE et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006 49 : 2049 2057.
5. Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Ligueros SM et al. Effects of dipeptidyl peptidase 4 inhibition on gastrointestinal function, meal appearance and glucose metabolism in type 2 diabetes. Diabetes 2007 56 : 1475 1480.
6. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007 39 : 218 223.
7. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007 76 : 132 138.
8. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004 27 : 2874 2880.
9. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007 30 : 890 893.
10. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007 9 : 166 174.
11. Rosenstock J, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared to component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007 9 : 175 185.
12. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006 49 : 1711 1721.
13. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007 30 : 217 223.
14. 1c over one year in drug-naïve patients with type 2 diabetes. Diabet Med 2007 24 : 955 961.
15. Baron AD. Postprandial hyperglycaemia and α-glucosidase inhibitors. Diabetes Res Clin Pract 1998 40 (Suppl. 51 55.
16. Deacon CF, Holst JJ. Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes. Int J Biochem Cell Biol 2006 38 : 831 844.
17. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003 26 : 881 885.
18. van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van WC. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005 28 : 154 163.
19. Wolever TM, Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW et al. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. Int J Obes Relat Metab Disord 1997 21 : 756 763.
20. Kim D, Macconell L, Zhuang D, Kothare PA, Trautmann M, Fineman M et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007 30 : 1487 1493.